Matches in SemOpenAlex for { <https://semopenalex.org/work/W2405958927> ?p ?o ?g. }
- W2405958927 endingPage "15" @default.
- W2405958927 startingPage "1" @default.
- W2405958927 abstract "Overview The discovery and development of oncology drugs are complex and associated with a high failure rate. For example, the chance of a new drug that enters clinical trial has an approximately 10% chance of achieving regulatory approval and ultimately becoming available for patients. Determining the proper dose and schedule of a drug are arguably the two most important determinants of both safety and efficacy, the primary determinants of regulatory approval. Understanding how to best estimate the proper dose and schedule for the many types of therapeutic agents now widely available and in development is a critical skill for those in the drug discovery and development field. This area of expertise has been made more complex with the addition of biological agents such as monoclonal antibodies, alternative protein scaffolds, and vaccines to that of hormones and small molecule platforms. In this chapter, we review the basic principles that underlie the appropriate selection of dose and schedule, with a major focus on cytotoxic chemotherapy. In addition, we discuss the many variables that can underlie the dose–response relationship including characteristics of the tumor, the tumor microenvironment, the host including enzymes of drug metabolism, and mechanisms of drug clearance. Finally, we review the clinical trial designs that have been successfully used to properly select dose and schedule for oncology drugs. The field of dose, schedule, and combination of chemotherapy agents has seen comparatively few developments in the past few years, as the focus of oncology progressively shifted from the so‐called traditional cytotoxic agents to target agents, and more recently to immunotherapy. Nevertheless, notably in the breast cancer field, dose dense chemotherapy regimens have come to the fore following the GIM‐2 trial. 1 It would be valuable to cite this published study, the ovarian cancer study GOG–0252 and breast cancer PANTHER study, as well as the recently presented meta‐analysis of dose dense trial by the EBCTCG presented at SABCS 2017. 2,3 ( ) Furthermore, two additional strategies have risen in the recent decades—in the advanced setting, the use of maintenance chemotherapy with either the reduction of current regimens or switching for non‐cross‐resistant drugs. 4–9 In the early setting, the combination of neoadjuvant therapy followed by postneoadjuvant therapy for select patients without adequate response at surgery, 10 and citing the potential of precision medicine to contribute to dose and combination design, chiefly through the evolving field of pharmacogenomics as well tumor mutation panels that are currently being tested. 11–14 The final segment, giving a panoramic view of an “integrated approach to cancer chemotherapy” should also mention the potential contributions of liquid biopsy strategies. 15,16 Finally, the field of immunotherapy has grown exponentially. Though a specific chapter is likely dedicated to the topic of immunotherapy, the potential of chemotherapy + immunotherapy combinations, both concomitant and sequentially, with chemotherapy acting as a “booster” would be interesting. 17 The TONIC trial presented during ESMO 2017 serves as a good example of the potential of this strategy.( )" @default.
- W2405958927 created "2016-06-24" @default.
- W2405958927 creator A5045982804 @default.
- W2405958927 creator A5089449477 @default.
- W2405958927 date "2019-12-06" @default.
- W2405958927 modified "2023-09-26" @default.
- W2405958927 title "Principles of Dose, Schedule, and Combination Therapy" @default.
- W2405958927 cites W1008859290 @default.
- W2405958927 cites W1262485082 @default.
- W2405958927 cites W1558085296 @default.
- W2405958927 cites W1671049130 @default.
- W2405958927 cites W1754065147 @default.
- W2405958927 cites W1795564265 @default.
- W2405958927 cites W1842248410 @default.
- W2405958927 cites W1867963032 @default.
- W2405958927 cites W1890647543 @default.
- W2405958927 cites W1899541887 @default.
- W2405958927 cites W1909111805 @default.
- W2405958927 cites W1909650807 @default.
- W2405958927 cites W1910716144 @default.
- W2405958927 cites W1917341586 @default.
- W2405958927 cites W1924785021 @default.
- W2405958927 cites W1927722732 @default.
- W2405958927 cites W1930683464 @default.
- W2405958927 cites W1955033393 @default.
- W2405958927 cites W1958673254 @default.
- W2405958927 cites W1965370740 @default.
- W2405958927 cites W1969592782 @default.
- W2405958927 cites W1970962784 @default.
- W2405958927 cites W1971821333 @default.
- W2405958927 cites W1974721564 @default.
- W2405958927 cites W1977887541 @default.
- W2405958927 cites W1979400471 @default.
- W2405958927 cites W1979404467 @default.
- W2405958927 cites W1982230933 @default.
- W2405958927 cites W1983075270 @default.
- W2405958927 cites W1988997790 @default.
- W2405958927 cites W1992984652 @default.
- W2405958927 cites W1996830477 @default.
- W2405958927 cites W1997353354 @default.
- W2405958927 cites W1999356404 @default.
- W2405958927 cites W2000292756 @default.
- W2405958927 cites W2002268410 @default.
- W2405958927 cites W2005328285 @default.
- W2405958927 cites W2006511094 @default.
- W2405958927 cites W2007520167 @default.
- W2405958927 cites W2017758955 @default.
- W2405958927 cites W2021467371 @default.
- W2405958927 cites W2021867415 @default.
- W2405958927 cites W2023300542 @default.
- W2405958927 cites W2023553772 @default.
- W2405958927 cites W2024131269 @default.
- W2405958927 cites W2025897602 @default.
- W2405958927 cites W2028156849 @default.
- W2405958927 cites W2029310066 @default.
- W2405958927 cites W2030087686 @default.
- W2405958927 cites W2031507616 @default.
- W2405958927 cites W2032684239 @default.
- W2405958927 cites W2033442994 @default.
- W2405958927 cites W2033989981 @default.
- W2405958927 cites W2035088306 @default.
- W2405958927 cites W2038424578 @default.
- W2405958927 cites W2040483342 @default.
- W2405958927 cites W2041014150 @default.
- W2405958927 cites W2042590058 @default.
- W2405958927 cites W2046705094 @default.
- W2405958927 cites W2055983050 @default.
- W2405958927 cites W2058037667 @default.
- W2405958927 cites W2060311941 @default.
- W2405958927 cites W2071874725 @default.
- W2405958927 cites W2077841029 @default.
- W2405958927 cites W2078003307 @default.
- W2405958927 cites W2079025304 @default.
- W2405958927 cites W2083616014 @default.
- W2405958927 cites W2090431728 @default.
- W2405958927 cites W2091091750 @default.
- W2405958927 cites W2091213994 @default.
- W2405958927 cites W2092015388 @default.
- W2405958927 cites W2096235803 @default.
- W2405958927 cites W2098775844 @default.
- W2405958927 cites W2101760255 @default.
- W2405958927 cites W2105886206 @default.
- W2405958927 cites W2106612113 @default.
- W2405958927 cites W2109134893 @default.
- W2405958927 cites W2109498035 @default.
- W2405958927 cites W2112163451 @default.
- W2405958927 cites W2112351355 @default.
- W2405958927 cites W2115100262 @default.
- W2405958927 cites W2117692326 @default.
- W2405958927 cites W2119505091 @default.
- W2405958927 cites W2121546200 @default.
- W2405958927 cites W2122122462 @default.
- W2405958927 cites W2123528875 @default.
- W2405958927 cites W2124268018 @default.
- W2405958927 cites W2124451268 @default.
- W2405958927 cites W2125519805 @default.
- W2405958927 cites W2128002599 @default.
- W2405958927 cites W2129931005 @default.